FDA MedWatch

Nationwide recall due to reports of a memory chip failure which could render the AED inoperable and prevent it from delivering therapy when indicated.

Field removal of the catheter due to reports that the catheter could kink or ovalize in certain anatomical situations, lead to difficulty in catheter advancement and/or delivery of other devices through the guide catheter

The change will result in 10% reduction in the potency of the heparin marketed in the U.S. and may have clinical significance in some situations, such as when heparin is administered as a bolus intravenous dose and an immediate anticoagulant effect is clinically important

Nationwide recall of Neocate Infant Specialized Formula, Lot # P91877, due to a manufacturing error that resulted in protein levels lower than that declared on the label.

Voluntary recall because of potential manufacturing problems.

Early Communication describing an increased number of adverse events and deaths in patients using Exjade who are over sixty years old who have myelodysplastic syndrome (MDS).

Cases of acute pancreatitis reported in patients treated with sitagliptin.

Class I Recall due to possibility of obstruction or disruption of therapy. Posted 09/24/2009

Pharmacists and pediatrics healthcare profesionals notified of risk of medication dosing errors

FDA continues to receive reports of progressive multifocal leukoencephalopathy (PML) in patients receiving Tysabri.